A neutropenia suggesting an interaction between valacyclovir and mycophenolate mofetil
Related Experiment Videos
Bernard Royer1, Gilbert Zanetta, Michel Bérard
1Pharmacology Department, Jean Minjoz University Hospital, Besançon, France. bernard.royer@ufc-chu.univ-fcomte.fr
Abstract:
Mycophenolate mofetil (MMF) is a drug which decreases the frequency of renal transplantation rejection. However, cytomegalovirus infections are a common feature of this treatment leading the physicians to prescribe antiviral prophylactic drugs like valacyclovir. During this association, neutropenia occur and the cause of this adverse effect is difficult to define. This report presents a case of neutropenia in a woman treated with MMF and valacyclovir. As the duration of the valacyclovir treatment exactly corresponds to the neutropenia duration, and the mycophenolate trough levels increased with the neutrophil count, the responsibility of this neutropenia was ascribed to valacyclovir. However, an examination of the literature for cases of neutropenia led to the suspicion of an interaction between MMF and valacyclovir. Mycophenolate may increase intracellular concentrations of valacyclovir up to haematotoxic levels. This mechanism may explain the interaction and further research is needed to confirm this interaction.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Drug Interactions
Antiviral Nucleoside Inhibitors
Cytomegalovirus Disease
Drug Toxicity: Risk factors